uniQure reports Q2 net loss $81.1M; AMT-130 BLA submission on track for Q3 2026

uniQure N.V.

Net loss $81.1M ($1.22/share) vs $37.7M ($0.69) in Q2 2025; revenue $5.8M (+$0.5M).
Cash $810.3M after $259M June offering; runway into 2030.
AMT-130 BLA submission for Huntington's on track for Q3 2026; four-year data expected Sept 2026.
AMT-260 Phase I/IIa: 3 of 6 patients had 79-100% seizure reduction; no SAEs related to drug.
AMT-191 Fabry data: dose-dependent α-Gal A activity up to 229.6x normal; all 11 patients off ERT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.